Conference reports

Keystone HIV Pathogenesis and Vaccine Development Report 12-18 April 2004, Whistler, British Columbia, Canada

Keystone HIV Pathogenesis and Vaccine Report

10th Anniversary Conference of the British HIV Association (BHIVA), 15–17 April 2004, Cardiff

BHIVA 2003-4 audit on HIV and pregnancy

More positive children are surviving into adult life and require tailored services

Other news from 10th BHIVA conference

5th International Workshop on Clinical Pharmacology of HIV Therapy, 1-3 April 2004, Rome, Italy

Large reductions in plasma PK levels of saquinavir, amprenavir and lopinavir/r levels when given with tipranavir/ritonavir

Good generic drugs and good adherence in Rwanda

Steady state PK of nelfinavir and M8 in pregnancy

Higher nelfinavir concentrations improve response in children

PK of once daily lopinavir/r in children

2nd European HIV Drug Resistance Workshop, 11-13 March 2004, Rome, Italy

Understanding developments in HIV drug resistance for new drugs and targets — atazanavir, fusion (T-20) and receptor inhibitors

11th Conference on Retroviruses and Opportunistic Infections (CROI), 8-11 February 2004, San Francisco

HIV-associated dementia and cognitive dysfunction

Diabetes and HIV and HCV; aging/HIV and diabetes

11th Conference on Retroviruses and Opportunistic Infections (CROI)

Drug levels can persist for more than two weeks after stopping efavirenz

Race affects absorption and clearance of efavirenz

Triple PI interactions: atazanavir increases saquinavir levels in ritonavir-boosted once-daily combination

Triple PI interactions: fosamprenavir and Kaletra interaction is difficult to overcome

Ribavirin (RBV) does not alter intracellular levels of AZT, 3TC or d4T

COLATE study shows no clinical benefit from continuing 3TC to maintain M184V mutation

Studies of new pipeline drugs

Little benefit seen for treatment during acute infection

Summary of resistance studies at Retrovirus

Update on peripheral neuropathy in HIV-infection

Smoking marijuana provides analgesic effect on HIV neuropathy

Two D:A:D updates: cardiovascular risk from HAART, and predictors of hypertension and changes in blood pressure

Low-dose rHGH maintains reductions in abdominal fat for 60 weeks

Rosiglitazone shows no benefit for lipoatrophy

Hypertension related to HAART in HIV-positive women

Testosterone therapy for women with low androgen levels or body weight

Nevirapine, pregnancy and adverse events

Prior nevirapine exposure for pregnant women can contribute to treatment failure

Conflicting findings with HAART use in pregnancy and prematurity

Antiretrovirals, mode of delivery and transmission risk

Tenofovir studies in children

Increase of non-AIDS defining cancers in HOPS cohort

HIV/HCV coinfection: superiority of pegylated interferon plus ribavirin, but lower response rate compared to mono-infected patients, especially for genotype-1

Epoetin-alfa improves interferon/ribavirin-associated anaemia

9th European AIDS Conference (EACS), 25-29 October 2003, Warsaw

Lower doses of d4T produce similar efficacy and reduced side effects

Switching from efavirenz to nevirapine to avoid CNS side effects

Interruption of treatment is safe for those who started too early

T20 is cost effective for UK purchasers

Intrauterine exposure to efavirenz

African patients and adherence in the UK

Five-year results of Kaletra-based therapy in treatment-naïve HIV patients

IL-2 effectively increases CD4 count in people with low CD4 nadir

Hepatitis coinfection: incidence in Europe and response to transplant

Rituximab plus CDE for HIV-related Non-Hodgkins Lymphoma (NHL)

13th International Conference on AIDS and STIs in Africa (ICASA), 21-26 September 2003, Nairobi

STIs in resource limited settings

43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 14-17 September 2003, Chicago

ddI may retain activity in nucleoside experienced patients

Studies and strategies with existing drugs

Incremental progress with new antiviral drugs

Newer nucleoside analogues show fewer adverse effects

43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 14-17 September 2003, Chicago

South African AIDS Conference, 3-6 August 2003, Durban

Township project is a model for care in resource poor settings

Projects band together to buy lowest-cost generic drugs

MTCT-Plus operates in Cote D’Ivoire, Kenya, Mozambique, Rwanda, South Africa, Thailand, Uganda and Zambia

Post navigation